20151223_TIME Ph2b Lancet Oncology 2015_PR EN
Category: 2015
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication
A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates
Stephane Leung-Theung-Long, et al. PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article Publication
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial
John Nemunaitis, et al. SITC 2015, November 2015 – Abstract available on the SITC website Download the poster here Poster Presentation
Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
20151112 SillaJen_Pexavec_Joint
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
20151103 TG1050 FINAL VERSION US
Transgene Reports Third Quarter 2015 Financial Results
20151021 PR US Q3 2015 FINAL
Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
23092015 PR ladenburg conf_EN
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication
Transgene Reports Financial Results for First Six Months of 2015 (interim report)
20150910 – PR 2015 H1 results final
